Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab

Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL), a member of the tumor necrosis factor receptor superfamily essential for osteoclastogenesis. Denosumab treatment is associated with a rapid, sustained, and reversible reduction in bone turno...

Descripción completa

Detalles Bibliográficos
Autores principales: Anastasilakis, Athanasios D, Toulis, Konstantinos A, Polyzos, Stergios A, Anastasilakis, Chrysostomos D, Makras, Polyzois
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3387828/
https://www.ncbi.nlm.nih.gov/pubmed/22767993
http://dx.doi.org/10.2147/TCRM.S24239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3387828/
https://www.ncbi.nlm.nih.gov/pubmed/22767993
http://dx.doi.org/10.2147/TCRM.S24239

Ejemplares similares